Blood lipid profiles as a prognostic biomarker in idiopathic pulmonary fibrosis

Respir Res. 2024 Jul 18;25(1):285. doi: 10.1186/s12931-024-02905-z.

Abstract

Background: Dysregulation of lipid metabolism is implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF). However, the association between the blood lipid profiles and the prognosis of IPF is not well defined. We aimed to identify the impacts of lipid profiles on prognosis in patients with IPF.

Methods: Clinical data of 371 patients with IPF (145 and 226 in the derivation and validation cohorts, respectively), including serum lipid profiles (total cholesterol, triglyceride, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, apolipoprotein A-I [Apo A-I], and apolipoprotein B), were retrospectively collected. The association with mortality was analyzed using the Cox proportional hazard model.

Results: In the derivation cohort, the mean age was 67.5 years, 86.2% were men, and 30.3% died during the follow-up (median: 18.0 months). Non-survivors showed lower lung function and greater gender-age-physiology scores than survivors. Among the serum lipid profiles, the levels of triglyceride and Apo A-I were significantly lower in non-survivors than in survivors. In the multivariate Cox analysis, low Apo A-I levels (< 140 mg/dL) were independently associated with the risk of mortality (hazard ratio 3.910, 95% confidence interval 1.170-13.069; P = 0.027), when adjusted for smoking history, body mass index, GAP score, and antifibrotic agent use. In both derivation and validation cohorts, patients with low Apo A-I levels (< 140 mg/dL) had worse survival (median survival: [derivation] 34.0 months vs. not reached, P = 0.003; [validation] 40.0 vs. 53.0 months, P = 0.027) than those with high Apo A-I levels in the Kaplan-Meier survival analysis.

Conclusions: Our results indicate that low serum Apo A-1 levels are an independent predictor of mortality in patients with IPF, suggesting the utility of serum Apo A-I as a prognostic biomarker in IPF.

Keywords: Apolipoprotein A-I; GAP score; Idiopathic pulmonary fibrosis; Mortality.

MeSH terms

  • Aged
  • Apolipoprotein A-I / blood
  • Biomarkers* / blood
  • Cohort Studies
  • Female
  • Follow-Up Studies
  • Humans
  • Idiopathic Pulmonary Fibrosis* / blood
  • Idiopathic Pulmonary Fibrosis* / diagnosis
  • Idiopathic Pulmonary Fibrosis* / mortality
  • Lipids* / blood
  • Male
  • Middle Aged
  • Prognosis
  • Retrospective Studies

Substances

  • Biomarkers
  • Lipids
  • Apolipoprotein A-I